2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Emerging Technologies, Profiling, Treatment Considerations, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality Improvement, Diseases, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult
PAPER

2077 Myelodysplastic/myeloproliferative neoplasms, not CMML: Clinical, genotype, and survival comparisons between disease subcategories among 249 patients

Ali Alsugair, MBBS, Michal Martinek2, Merry Nakhleh3, Shivani Udyawar4, Saubia Fathima, MD5, Abhishek Avinash Mangaonkar, MBBS6, Attilio Orazi7, Daniel Arber, MD8, Rong He, MD9, Kaaren Reichard, MD10, Cinthya J Zepeda Mendoza11, Dong Chen, MD, PhD12, David Viswanatha, MD13, Animesh Pardanani, PhD, MBBS14, Naseema Gangat, MBBS15, Mrinal M. Patnaik, MD, MBBS16, Ayalew Tefferi, MD17
1 Mayo Clinic, Rochester, United States
2 Mayo Clinic, Rochester, United States
3 Mayo Clinic, Rochester, United States
4 Mayo Clinic, Rochester, United States
5 Mayo Clinic, Rochester, United States
6 Mayo Clinic, Rochester, United States
7 Texas Tech University Health Sciences Center, El Paso, United States
8 University of Chicago, Chicago, United States
9 Mayo Clinic, Rochester, United States
10 Mayo Clinic, Rochester, United States
11 Mayo Clinic, Rochester, United States
12 Mayo Clinic, Rochester, United States
13 Mayo Clinic, Rochester, United States
14 Mayo Clinic, Rochester, United States
15 Mayo Clinic, Rochester, United States
16 Mayo Clinic, Rochester, United States
17 Mayo Clinic, Rochester, United States

Background:

Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) include chronic myelomonocytic leukemia (CMML) and other less characterized entities including atypical chronic myeloid leukemia (aCML), MDS/MPN with SF3B1 mutation and thrombocytosis (MDS/MPN-SF3B1-T), MDS/MPN with ring sideroblasts and thrombocytosis, not otherwise specified (MDS/MPN-RS-T, NOS), MDS/MPN, not otherwise specified (MDS/MPN, NOS); the latter includes the provisional entity of MDS/MPN with isolated isochromosome (17q) [MDS/MPN with i(17q)]. The current study compares clinical and laboratory features and survival outcomes between MDS/MPN subcategories, excluding CMML.

Methods:

Patients were retrospectively recruited from Mayo Clinic databases. MDS/MPN diagnosis and sub-categorization were rendered/confirmed by Mayo Clinic pathologists following ICC criteria (Arber et al. Blood 2022;140:1200). Overall survival (OS) and cumulative incidence of blast transformation (BT) rates were adjusted for allogeneic stem cell transplantation (ASCT) and competing risk, respectively.

Results:

A total of 249 Mayo Clinic patients with MDS/MPN, not CMML were included (median age 72 years, 59% males): MDS/MPN-SF3B1-T (N=97 [39%]; median age 71 years, 51% males), MDS/MPN-RS-T, NOS (N=16 [6%]; median age 76 years, 37% males), MDS/MPN, NOS (N=107 [42%], median age 73 years, 67% males), and aCML (N=29 [11%], median age 70 years, 65% males); MDS/MPN with i(17q) [N=5 (2%); median age 80 years, 80% males] was included in the MDS/MPN, NOS group because of the small sample size and not to undermine its unique features and dismal prognosis. Age (p=0.07) and sex (p=0.03) distributions were different among the subgroups, as indicated above. Respective frequencies of red blood cell transfusion need at presentation were 12%, 13%, 36%, and 41% (p<0.01), palpable splenomegaly 25%, 0%, 43%, and 59% (p<0.01), and abnormal karyotype 15%, 20%, 47%, and 44% (p<0.01). Significant differences in mutation distribution were apparent for SF3B1 (expected), JAK2, ASXL1, SRSF2, NRAS, KRAS, CBL, U2AF1, SETBP1, and EZH2. The groups also differed in platelet count (expected), leukocyte count (p<0.01), peripheral and bone marrow blast count (p<0.01), and absolute neutrophil (ANC), monocyte (AMC), lymphocyte (ALC), eosinophil (AEC) and basophil (ABC) counts (p<0.01 for all).

At a median follow-up of 58 months, 120 (48%) deaths, 22 (9%) BT, and 40 (16%) ASCTs were documented. Median OS for the entire cohort was 48 months; respective median transplant-censored OS in the MDS/MPN-SF3B1-T, MDS/MPN-RS-T, NOS, MDS/MPN, NOS, and aCML were 165, 90, 20, and 15 months (p<0.01); OS was not significantly different between the first two (p=0.23) and the last two (p=0.49) groups. The results were similar when analysis excluded patients with MDS/MPN with i(17q) from the MDS/MPN, NOS group; the specific entity was associated with dismal prognosis (median OS 4 months), which was significantly worse than all other subgroups. In multivariable analysis, subcategory-specific risk factors included age (p<0.01) and hemoglobin level (p=0.03) in MDS/MPN-SF3B1-T, age (p=0.01), PB blast % (p=0.01), red blood cell (RBC) transfusion need (p<0.01) in MDS/MPN, NOS, and age (p=0.01) and hemoglobin level (p=0.01) in aCML. Kaplan-Meier estimates of OS between transplanted and non-transplanted patients were significantly different in MDS/MPN, NOS (median 162 vs. 18 months; p<0.01) and aCML (median 48 vs. 13 months; p<0.01), but not in the other two groups (p=0.5-0.7); after adjusting for immortal time bias, the favorable impact of ASCT in MDS/MPN, NOS was sustained while an unfavorable impact in MDS/MPN-SF3B1-T was suggested (p<0.01). Competing risk-adjusted cumulative incidence of BT at 5 years was 16.5% in MDS/MPN, NOS, 12.1% in aCML, 2.5% in MDS/MPN-SF3B1-T, and 6.7% in MDS/MPN-RS-T (Gray’s test p=0.03).

Conclusion

MDS/MPN represent a heterogenous disease category with significant inter-group differences in genetic and phenotypic characteristics that contribute to the disparate survival outcomes. The current study highlights strong similarities in phenotype and survival outcome between MDS/MPN-SF3B1-T and MDS/MPN-RS-T, NOS as well as between  aCML and MDS/MPN, NOS, suggesting possible simplification of disease classification by merging the annotated subgroups, with the caveat that MDS/MPN with i(17q) might require different disease group allocation.

Ali Alsugair, MBBS: No relevant conflicts of interest to declare.